Stem Cell Therapy for Epidermolysis Bullosa

Recruiting in Palo Alto (17 mi)

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: RHEACELL GmbH & Co. KG

Disqualifiers: Tumor diseases, Allergies, Pregnancy, others

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a special cell therapy given through an IV to people with a severe genetic skin condition called RDEB. The therapy aims to help heal and grow new, healthy skin. Researchers are evaluating its safety and effectiveness. Previous tests have shown increased collagen expression and faster wound healing in patients with RDEB.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. However, if you are currently or have recently been in another clinical trial, you may not be eligible to participate.

What data supports the effectiveness of the treatment allo-APZ2-OTS for Epidermolysis Bullosa?

Research shows that ABCB5+ mesenchymal stem cells, a component of allo-APZ2-OTS, have been effective in reducing disease activity, itch, and pain in patients with recessive dystrophic epidermolysis bullosa, a severe skin disorder. These stem cells have shown potential in promoting wound healing and improving quality of life in clinical trials. ^{1 2 3 4 5}

Is stem cell therapy for epidermolysis bullosa safe?

Research on ABCB5+ mesenchymal stem cells (MSCs) for treating epidermolysis bullosa shows that the treatment is generally well-tolerated. In a clinical trial, some patients experienced mild side effects like lymphadenopathy (swollen lymph nodes) and hypersensitivity reactions, but these were manageable and resolved without lasting issues. ^{1 2 4 5 6}

How is the treatment allo-APZ2-OTS different from other treatments for epidermolysis bullosa?

The treatment allo-APZ2-OTS uses ABCB5-positive mesenchymal stem cells (a type of cell that can help reduce inflammation and promote healing) derived from skin, which is unique compared to other treatments that may use stem cells from different sources like umbilical cord blood or adipose tissue. This therapy is administered intravenously (through the veins) and has shown potential in reducing disease activity, itch, and pain in patients with recessive dystrophic epidermolysis bullosa, a condition with no effective standard treatment. ^{1 2 3 4 7}

Research Team

Eligibility Criteria

This trial is for males and females from 6 months old with confirmed recessive dystrophic epidermolysis bullosa (RDEB). Participants must have a specific wound type, be in good general health, and understand the study. Women who can have children need a negative pregnancy test and agree to use birth control.

Inclusion Criteria

Subject is eligible to participate in this clinical trial based on general health condition

I have RDEB confirmed by genetic testing or skin biopsy.

My wound is between 5-50 cm2, older than 21 days but less than 9 months, and not infected.

Exclusion Criteria

Clinically significant or unstable concurrent disease or other clinical contraindications like an uncontrolled or poorly controlled mental health condition of the subject and/or his/her legal representative that could impact on patient's safety or interfere with study compliance such as inability to attend scheduled study visits

Employees of the sponsor, or employees or relatives of the investigator

Previous participation in this clinical trial (except for screening failures)

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intravenous administration of allo-APZ2-OTS or placebo

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• allo-APZ2-OTS (Mesenchymal Stromal Cells)
• Placebo (Other)

Trial Overview The trial tests allo-APZ2-OTS, an intravenous treatment for RDEB against a placebo. The goal is to see if it's safe and works better than not receiving the active treatment.

Participant Groups

Group I: Verum Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

RHEACELL GmbH & Co. KG

Lead Sponsor

Trials

11

Recruited

680+

Findings from Research

In a phase I/IIa clinical trial involving 16 patients with recessive dystrophic epidermolysis bullosa (RDEB), treatment with ABCB5+ mesenchymal stem cells (MSCs) showed a statistically significant reduction in disease activity scores, indicating potential efficacy as a disease-modifying therapy.

The treatment was well-tolerated, with only three adverse events related to the cell product, all of which were manageable and resolved without lasting effects, suggesting a favorable safety profile for ABCB5+ MSCs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. Kiritsi, D., Dieter, K., Niebergall-Roth, E., et al.[2022]

In a clinical trial involving 16 patients with recessive dystrophic epidermolysis bullosa (RDEB), treatment with ABCB5+ mesenchymal stromal cells led to a significant closure of 64.9% of wounds by week 12, with many wounds closing as early as day 17 or 35.

The treatment not only facilitated wound closure but also significantly reduced the rate of new wound formation by 79.3%, suggesting a promising therapeutic efficacy for ABCB5+ MSCs in managing RDEB.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Dieter, K., Niebergall-Roth, E., Daniele, C., et al.[2023]

The use of allogeneic adipose-derived mesenchymal stem cells (ADMSC) in a patient with recessive dystrophic epidermolysis bullosa (RDEB) showed significant long-lasting improvements in wound healing, pain, and quality of life, with effects observed up to 2 years after treatment.

ADMSC treatment was well-tolerated and correlated with changes in immune response and levels of profibrotic factors, suggesting a potential new therapeutic option for patients who do not respond to conventional treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. Maseda, R., Martínez-Santamaría, L., Sacedón, R., et al.[2020]

ABCB5+ mesenchymal stem cells (MSCs) from discarded skin samples show strong potential for treating chronic skin wounds and inflammatory diseases, demonstrating effective immunomodulatory and wound healing properties.

The FDA has approved a phase III trial for ABCB5+ MSCs in treating recessive dystrophic epidermolysis bullosa, and they are now accessible for treating chronic venous ulcers in Germany, highlighting their promising therapeutic applications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Skin-Derived ABCB5+ Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine. Niebergall-Roth, E., Frank, NY., Ganss, C., et al.[2023]

ABCB5+ dermal mesenchymal stem cells (DSCs) show superior ability to migrate and engraft in skin wounds compared to bone marrow-derived MSCs, suggesting they may be more effective for treating skin conditions like recessive dystrophic epidermolysis bullosa (RDEB).

The unique expression of HOXA3 in ABCB5+ DSCs may enhance their skin homing properties, which could lead to improved wound healing and has potential implications for broader regenerative medicine applications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment. Riedl, J., Pickett-Leonard, M., Eide, C., et al.[2022]

Bone marrow contains specific cells that can help heal skin wounds and correct defects in the skin's structure, particularly in conditions like epidermolysis bullosa (EB), a genetic skin disease.

Research indicates that the beneficial epithelial progenitors for skin repair come from a specific type of bone marrow stem cell, known as PDGFRalpha-positive mesenchymal stem cells, highlighting their potential for therapeutic use in treating EB.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Stem cell therapy for intractable skin diseases]. Tamai, K.[2012]

References

1. United States pubmed.ncbi.nlm.nih.gov

Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. [2022]

2. England pubmed.ncbi.nlm.nih.gov

ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. [2023]

3. United States pubmed.ncbi.nlm.nih.gov

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients. [2021]

4. Switzerland pubmed.ncbi.nlm.nih.gov

Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. [2020]

5. Switzerland pubmed.ncbi.nlm.nih.gov

Skin-Derived ABCB5+ Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine. [2023]

6. England pubmed.ncbi.nlm.nih.gov

ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment. [2022]

7. Japan pubmed.ncbi.nlm.nih.gov

[Stem cell therapy for intractable skin diseases]. [2012]